Abstract
Nevirapine resistance has been detected in a considerable proportion of women after single-dose nevirapine (SD-NVP) for the prevention of mother-to-child human immunodeficiency virus-1 transmission. As a result, concern has been raised about the effectiveness of subsequent nevirapine-based treatment. Studies in Thailand, Botswana, and South Africa have assessed virologic treatment response after SD-NVP. These studies did not find any significant difference in virologic response for women who began treatment >6 months after SD-NVP exposure. Two studies found worse response rates in women when treatment was initiated within 6 months of SD-NVP exposure. Furthermore, 2 studies found no difference in human immunodeficiency virus transmission rates from mother to child after the receipt of SD-NVP in repeat pregnancies. These data support the use of SD-NVP as 1 option for the prevention of mother-to-child human immunodeficiency virus-1 transmission in resource-limited settings, particularly in settings where more complex regimens are not yet available. Further research in the optimization of perinatal prevention regimens is needed.
Original language | English (US) |
---|---|
Pages (from-to) | S56-S63 |
Journal | American journal of obstetrics and gynecology |
Volume | 197 |
Issue number | 3 SUPPL. |
DOIs | |
State | Published - Sep 2007 |
Keywords
- PMTCT
- nevirapine
- resistance
- treatment
ASJC Scopus subject areas
- Obstetrics and Gynecology